MA27528A1 - Composes calcilytiques - Google Patents

Composes calcilytiques

Info

Publication number
MA27528A1
MA27528A1 MA28294A MA28294A MA27528A1 MA 27528 A1 MA27528 A1 MA 27528A1 MA 28294 A MA28294 A MA 28294A MA 28294 A MA28294 A MA 28294A MA 27528 A1 MA27528 A1 MA 27528A1
Authority
MA
Morocco
Prior art keywords
calcilytic compounds
compounds
calcilytic
methods
novel calcilytic
Prior art date
Application number
MA28294A
Other languages
English (en)
Inventor
W Marquis Robert
N Casillas Linda
M Ramanjulu Joshi
Francis Callahan James
Original Assignee
Smithkline Beecham Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beecham Corp filed Critical Smithkline Beecham Corp
Publication of MA27528A1 publication Critical patent/MA27528A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C217/00—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
    • C07C217/54—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C217/00—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
    • C07C217/02—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C217/04—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C217/28—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having one amino group and at least two singly-bound oxygen atoms, with at least one being part of an etherified hydroxy group, bound to the carbon skeleton, e.g. ethers of polyhydroxy amines
    • C07C217/30—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having one amino group and at least two singly-bound oxygen atoms, with at least one being part of an etherified hydroxy group, bound to the carbon skeleton, e.g. ethers of polyhydroxy amines having the oxygen atom of at least one of the etherified hydroxy groups further bound to a carbon atom of a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C217/00—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
    • C07C217/02—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C217/04—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C217/28—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having one amino group and at least two singly-bound oxygen atoms, with at least one being part of an etherified hydroxy group, bound to the carbon skeleton, e.g. ethers of polyhydroxy amines
    • C07C217/30—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having one amino group and at least two singly-bound oxygen atoms, with at least one being part of an etherified hydroxy group, bound to the carbon skeleton, e.g. ethers of polyhydroxy amines having the oxygen atom of at least one of the etherified hydroxy groups further bound to a carbon atom of a six-membered aromatic ring
    • C07C217/32—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having one amino group and at least two singly-bound oxygen atoms, with at least one being part of an etherified hydroxy group, bound to the carbon skeleton, e.g. ethers of polyhydroxy amines having the oxygen atom of at least one of the etherified hydroxy groups further bound to a carbon atom of a six-membered aromatic ring the six-membered aromatic ring or condensed ring system containing that ring being further substituted
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C217/00—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
    • C07C217/02—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C217/04—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C217/28—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having one amino group and at least two singly-bound oxygen atoms, with at least one being part of an etherified hydroxy group, bound to the carbon skeleton, e.g. ethers of polyhydroxy amines
    • C07C217/30—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having one amino group and at least two singly-bound oxygen atoms, with at least one being part of an etherified hydroxy group, bound to the carbon skeleton, e.g. ethers of polyhydroxy amines having the oxygen atom of at least one of the etherified hydroxy groups further bound to a carbon atom of a six-membered aromatic ring
    • C07C217/32—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having one amino group and at least two singly-bound oxygen atoms, with at least one being part of an etherified hydroxy group, bound to the carbon skeleton, e.g. ethers of polyhydroxy amines having the oxygen atom of at least one of the etherified hydroxy groups further bound to a carbon atom of a six-membered aromatic ring the six-membered aromatic ring or condensed ring system containing that ring being further substituted
    • C07C217/34—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having one amino group and at least two singly-bound oxygen atoms, with at least one being part of an etherified hydroxy group, bound to the carbon skeleton, e.g. ethers of polyhydroxy amines having the oxygen atom of at least one of the etherified hydroxy groups further bound to a carbon atom of a six-membered aromatic ring the six-membered aromatic ring or condensed ring system containing that ring being further substituted by halogen atoms, by trihalomethyl, nitro or nitroso groups, or by singly-bound oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/02—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C229/34—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton containing six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00—Systems containing two condensed rings
    • C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
    • C07C2602/04—One of the condensed rings being a six-membered aromatic ring
    • C07C2602/08—One of the condensed rings being a six-membered aromatic ring the other ring being five-membered, e.g. indane

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Pain & Pain Management (AREA)
  • Nutrition Science (AREA)
  • Immunology (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

L'invention concerne des nouveaux composés calcilytiques ainsi que des procédés permettant de les utiliser.
MA28294A 2002-11-26 2005-05-23 Composes calcilytiques MA27528A1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US42910502P 2002-11-26 2002-11-26

Publications (1)

Publication Number Publication Date
MA27528A1 true MA27528A1 (fr) 2005-09-01

Family

ID=32393505

Family Applications (1)

Application Number Title Priority Date Filing Date
MA28294A MA27528A1 (fr) 2002-11-26 2005-05-23 Composes calcilytiques

Country Status (33)

Country Link
US (6) US7514473B2 (fr)
EP (1) EP1569892B1 (fr)
JP (1) JP4489597B2 (fr)
KR (2) KR101142697B1 (fr)
CN (1) CN1325466C (fr)
AP (1) AP2113A (fr)
AR (1) AR042132A1 (fr)
AU (1) AU2003291157C1 (fr)
BR (1) BR0316544A (fr)
CA (1) CA2507226C (fr)
CO (1) CO5570664A2 (fr)
CY (1) CY1113083T1 (fr)
DK (1) DK1569892T3 (fr)
EA (1) EA009603B1 (fr)
ES (1) ES2388277T3 (fr)
HK (1) HK1082914A1 (fr)
IL (1) IL168704A (fr)
IS (1) IS2897B (fr)
MA (1) MA27528A1 (fr)
MX (1) MXPA05005574A (fr)
MY (1) MY143244A (fr)
NO (1) NO332304B1 (fr)
NZ (1) NZ540275A (fr)
OA (1) OA12962A (fr)
PE (1) PE20040845A1 (fr)
PL (1) PL211571B1 (fr)
PT (1) PT1569892E (fr)
SI (1) SI1569892T1 (fr)
TW (1) TWI316511B (fr)
UA (1) UA81642C2 (fr)
UY (1) UY28089A1 (fr)
WO (1) WO2004047751A2 (fr)
ZA (1) ZA200504104B (fr)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UY28089A1 (es) * 2002-11-26 2004-06-30 Smithkline Beecham Corp Compuestos calciliticos
EP1713758A4 (fr) * 2004-02-06 2008-02-13 Smithkline Beecham Corp Composes calcilytiques
TW200845956A (en) 2006-12-18 2008-12-01 Smithkline Beecham Corp Calcilytic compounds
DK2292592T3 (da) * 2008-06-05 2012-10-08 Asahi Kasei Pharma Corp Sulfonamidforbindelse og anvendelse deraf
CA2748250A1 (fr) * 2008-12-24 2010-07-01 Daiichi Sankyo Company, Limited Composes indanyle
GB201217330D0 (en) 2012-09-28 2012-11-14 Univ Cardiff Therapeutic for treating inflammatory lung disorders
WO2015196205A1 (fr) * 2014-06-20 2015-12-23 Glaxosmithkline Llc Procédé d'utilisation de composés calcilytiques pour traiter des maladies dues à des niveaux d'insuline ou de glucose anormaux

Family Cites Families (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE298506C (fr)
US643656A (en) * 1898-09-03 1900-02-20 Francis Keil Mold for lock-cylinders and key-hubs.
ES421076A1 (es) 1973-12-01 1976-04-01 Andreu Sa Dr Procedimiento para la obtencion de 1-ariloxi-3-aralquilami-no-2-propanoles.
ES442062A1 (es) 1975-10-24 1977-04-01 Andreu Sa Dr Procedimiento para la obtencion de 1-ariloxi-2-hidroxi-3- alquilaminopropanos.
DE2644833A1 (de) 1976-10-05 1978-04-20 Boehringer Sohn Ingelheim Neue 1-aryloxy-2-hydroxy-3-alkylenaminopropane und verfahren zu ihrer herstellung
CH618335A5 (fr) * 1977-05-31 1980-07-31 Arnegger Richard E
US4234595A (en) * 1977-07-13 1980-11-18 Mead Johnson & Company 3-Indolyl-tertiary butylaminopropanols
IL56369A (en) 1978-01-20 1984-05-31 Erba Farmitalia Alpha-phenoxybenzyl propanolamine derivatives,their preparation and pharmaceutical compositions comprising them
IT1101724B (it) * 1978-12-05 1985-10-07 Erba Carlo Spa Derivati morfolinici e fenossiprofanolaminici e procedimento per la loro preparazione
GB2014968A (en) 1978-02-24 1979-09-05 Pearson J Article handling apparatus
US4495352A (en) 1979-02-13 1985-01-22 Mead Johnson & Company Heterocyclic substituted aryloxy 3-indolyl-tertiary butylaminopropanols
ES480066A1 (es) 1979-04-28 1980-04-01 Especialid Latin Medicam Unive Procedimiento de obtencion de 1-4-cloro-&,&-dimetil-benceno-etanamino-2-oxi-3 ariloxi propanos.
DE3544172A1 (de) 1985-12-13 1987-06-19 Lentia Gmbh Neue kristalline salze von aryloxy-propanolaminen, verfahren zu ihrer herstellung und ihre verwendung
FR2601008B1 (fr) 1986-07-03 1990-03-30 Sanofi Sa Procede de synthese stereospecifique de derives de l'indole
DD298506A5 (de) * 1988-12-30 1992-02-27 Ernst-Moritz-Arndt-Universitaet Greifswald,De Verfahren zur herstellung halogensubstituierter 1-phenoxy-3-alkylamino-propan-2-ole
DE4040186A1 (de) 1989-12-20 1991-06-27 Hoechst Ag Hypoglykaemisch aktive propandiolaminderivate mit insulin-aehnlicher wirkung und deren verwendung, neue propandiolaminderivate, diese substanzen enthaltende pharmazeutische zubereitungen und ihre verwendung zur behandlung von krankheiten
HN1996000101A (es) * 1996-02-28 1997-06-26 Inc Pfizer Terapia combinada para la osteoporosis
US6818660B2 (en) 1996-04-09 2004-11-16 Nps Pharmaceuticals, Inc. Calcilytic compounds
WO1997037967A1 (fr) 1996-04-09 1997-10-16 Nps Pharmaceuticals, Inc. Composes calcilytiques
US20020019440A1 (en) 1996-11-05 2002-02-14 Virbac Sa Aryloxypropanolamine derivatives, method of preparation and applications thereof
TW483881B (en) 1996-12-03 2002-04-21 Nps Pharma Inc Calcilytic compounds
US7202261B2 (en) 1996-12-03 2007-04-10 Nps Pharmaceuticals, Inc. Calcilytic compounds
CA2285556A1 (fr) 1997-04-04 1998-10-15 Smithkline Beecham Corporation Composes calcilytiques
UY24949A1 (es) 1997-04-08 2001-04-30 Smithkline Beecham Corp Compuestos calcilíticos
WO1999051941A1 (fr) 1998-04-01 1999-10-14 Mannesmann Rexroth Ag Procede de calcul de la moyenne
AR014975A1 (es) 1998-04-08 2001-04-11 Nps Pharma Inc Compuestos calciliticos, una composicion farmaceutica que los comprende, y el uso de los mismos para la fabricacion de un medicamento
PE20000415A1 (es) 1998-04-08 2000-05-21 Smithkline Beecham Corp Compuestos calciliticos
US6335338B1 (en) 1998-08-12 2002-01-01 Smithkline Beecham Corporation Calcilytic compounds
WO2000009132A1 (fr) 1998-08-12 2000-02-24 Smithkline Beecham Corporation Composes calcilytiques
PE20001456A1 (es) 1999-02-02 2001-01-28 Smithkline Beecham Corp Compuestos calcioliticos
AU6050000A (en) 1999-07-22 2001-02-13 Eli Lilly And Company Improved method of treating type ii diabetes and obesity
ECSP003590A (es) 1999-07-31 2002-02-25 Smithkline Beecham Corp Compuestos calcioliticos
US20030018203A1 (en) 2002-07-17 2003-01-23 Largo Maria Amparo Calcilytic compounds
AR030684A1 (es) 2000-01-24 2003-09-03 Smithkline Beecham Corp Compuestos calciliticos, uso de dichos compuestos en la manufactura de medicamentos, e intermediarios utiles en la preparacion de dichos compuestos
CA2416537A1 (fr) 2000-07-21 2002-01-31 Smithkline Beecham Corporation Composes calcilytiques
EP1404654A4 (fr) 2000-10-25 2008-12-03 Smithkline Beecham Corp Composes calcilytiques
ATE343390T1 (de) 2000-10-25 2006-11-15 Smithkline Beecham Corp Kalzilytische verbindungen
WO2002072760A2 (fr) * 2001-03-08 2002-09-19 Smithkline Beecham Corporation Inhibiteurs d'helicase pcra
US6864267B2 (en) 2001-07-16 2005-03-08 Smithkline Beecham Corporation Calcilytic compounds
UY28089A1 (es) 2002-11-26 2004-06-30 Smithkline Beecham Corp Compuestos calciliticos
WO2004092120A2 (fr) 2003-04-07 2004-10-28 Nps Pharmaceuticals, Inc. Composes pyrimidinone en tant que calcilytiques
AU2004266705A1 (en) 2003-08-20 2005-03-03 Nitromed, Inc. Nitrosated and nitrosylated cardiovascular compounds, compositions and methods of use
WO2005030746A1 (fr) 2003-09-24 2005-04-07 Glaxo Group Limited Composes calcilytiques
AR045799A1 (es) 2003-09-24 2005-11-16 Glaxo Group Ltd Compuesto 6- oxo-2,5- dioxabiciclico y su uso para preparar una composicion farmaceutica
JP2007523076A (ja) * 2004-02-06 2007-08-16 スミスクライン・ビーチャム・コーポレイション カルシウム受容体アンタゴニスト化合物
NL1025457C1 (nl) 2004-02-11 2005-08-12 Rudolf Johannes Gerardus Hoorn Haspelrem.
AU2005304770A1 (en) 2004-11-08 2006-05-18 Nicox S.A. Nitrosated and nitrosylated compounds, compositions and methods for the treatment of ophthalmic disorders
CA2595579A1 (fr) 2005-01-21 2006-07-27 Nitromed, Inc. Compositions de groupes donneurs a base de monoxyde d'azote heterocyclique contenant des composes cardio-vasculaires, et methodes permettant de les utiliser

Also Published As

Publication number Publication date
PL211571B1 (pl) 2012-05-31
WO2004047751A3 (fr) 2004-08-19
KR20110124806A (ko) 2011-11-17
MY143244A (en) 2011-04-15
KR101142697B1 (ko) 2012-05-10
JP4489597B2 (ja) 2010-06-23
NO332304B1 (no) 2012-08-20
CA2507226A1 (fr) 2004-06-10
AR042132A1 (es) 2005-06-08
US8399517B2 (en) 2013-03-19
WO2004047751A2 (fr) 2004-06-10
US20090163589A1 (en) 2009-06-25
TWI316511B (en) 2009-11-01
KR20050086786A (ko) 2005-08-30
US9227914B2 (en) 2016-01-05
PL376965A1 (pl) 2006-01-09
AP2113A (en) 2010-03-04
US7829594B2 (en) 2010-11-09
EP1569892A2 (fr) 2005-09-07
DK1569892T3 (da) 2012-08-27
BR0316544A (pt) 2005-10-04
CY1113083T1 (el) 2016-04-13
MXPA05005574A (es) 2005-07-27
CN1325466C (zh) 2007-07-11
AU2003291157A1 (en) 2004-06-18
US7514473B2 (en) 2009-04-07
PT1569892E (pt) 2012-09-06
IL168704A (en) 2010-12-30
AP2005003320A0 (en) 2005-06-30
JP2006507348A (ja) 2006-03-02
CN1741985A (zh) 2006-03-01
ZA200504104B (en) 2006-03-29
IS2897B (is) 2014-09-15
EP1569892B1 (fr) 2012-06-13
US20110054021A1 (en) 2011-03-03
US20060058391A1 (en) 2006-03-16
TW200510276A (en) 2005-03-16
NZ540275A (en) 2007-11-30
AU2003291157C1 (en) 2011-05-12
ES2388277T3 (es) 2012-10-11
US8586631B2 (en) 2013-11-19
PE20040845A1 (es) 2004-11-28
HK1082914A1 (en) 2006-06-23
AU2003291157B2 (en) 2011-01-20
US20130158114A1 (en) 2013-06-20
UA81642C2 (ru) 2008-01-25
SI1569892T1 (sl) 2012-09-28
EP1569892A4 (fr) 2010-09-15
EA200500878A1 (ru) 2005-10-27
US20140057980A1 (en) 2014-02-27
US20150183723A1 (en) 2015-07-02
CA2507226C (fr) 2011-11-15
US8980950B2 (en) 2015-03-17
UY28089A1 (es) 2004-06-30
OA12962A (en) 2006-10-13
EA009603B1 (ru) 2008-02-28
CO5570664A2 (es) 2005-10-31
NO20053071L (no) 2005-06-22
IS7880A (is) 2005-06-02

Similar Documents

Publication Publication Date Title
MA27528A1 (fr) Composes calcilytiques
MA29154B1 (fr) Promedicament amide de gemcitabine, compositions et utilisations associees
MA29528B1 (fr) Agents de fixation
MA31606B1 (fr) Anticorps anti-cd 79b immunoconjugues et procedes d'utilisation
MA30497B1 (fr) Anticorps et immunco-conjugues, et leurs utilisations.
MXPA03004793A (es) Roedores transgenicos transcromosomales para elaborar anticuerpos humnanos.
EP1461442A4 (fr) Animaux transgeniques porteurs de genes a chaine legere lambda d'immunoglobuline humaine
CY1105137T1 (el) Παραγωγα αμινοκυκλοεξυλ αιθερων και χρησεις τους
BRPI0414599A (pt) pirrol-indóis substituìdos
CO5650191A2 (es) Cables compuestos multi-miembros separables
CR7182A (es) Benzoilsufanamidas y sulfonilbenzamidinas que se usan como agentes antitumorales
NO20041493L (no) Kjemiske forbindelser.
EP1836298A4 (fr) Compositions de synthetase d'aminoacyl-arnt et utilisations correspondantes
ZA200501054B (en) Transplant acceptance inducing cells of monocytic origin and their preparation and use.
AR038563A1 (es) Composicion de ziprasidona y controles sinteticos
EP1700120A4 (fr) Marqueur pour la neuromyelite optique
AU2889201A (en) Automatic water toxicity measuring apparatus
NO20060535L (no) Aztreonam-L-lysin og fremgangsmater for fremstilling av dette
CY1105980T1 (el) Βελτιωμενη διαδικασια παρασκευης υδροβρωμικου αλατος του αλφα-πολυμορφικου ελετριπτανιου
TW200613308A (en) Cyclobutanetetracarboxylate compound and preparation method thereof
AU2001258373A1 (en) Method for identifying helicobacter antigens
MXPA04003755A (es) Endoprotesis vasculares.
HK1088016A1 (en) Isolated fluorescent protein from clytia gregaria cgfp and use thereof
UA83203C2 (uk) Тіазол-(бі)циклоалкілкарбоксаніліди, засіб на їх основі та застосування для боротьби з небажаними мікроорганізмами
MXPA02008288A (es) Prouduccion de mamiferos que producen progenie de un solo sexo.